A few therapies derived from human medicine are available for dogs, but a very successful form of therapy by which antibodies inhibit tumor growth has not yet been available for animals. Now, scientists have developed, for the first time, antibodies to treat cancer in dogs.
A new study by radiation oncologists has found that proton beam therapy significantly improved disease free survival and tumor control when compared to IMRT in a variety of advanced head and neck cancers.
A team of researchers has shown for the first time that stem cells created using different methods produce differing cells. The findings provide new insights into the basic biology of stem cells and could ultimately lead to improved therapies.
New experiments have identified a compound that might halt the progression of Alzheimer’s by interfering with the role amyloid-beta plays in the formation of blood clots.
Supercomputer simulations have shown that clusters of a protein linked to cancer warp cell membranes, according to scientists at The University of Texas Health Science Center at Houston (UTHealth) Medical School. This research on these protein clusters, or aggregates as scientists call them, could help guide design of new anticancer drugs.
By scouring the DNA of thousands of patients, researchers have discovered four rare gene mutations that not only lower the levels of triglycerides, a type of fat in the blood, but also significantly reduce a person’s risk of coronary heart disease—dropping it by 40 percent. The mutations all cripple the same gene, called APOC3, suggesting a powerful strategy in developing new drugs against heart disease.
Computer simulations that reveal a key mechanism in the replication process of influenza A may help defend against future deadly pandemics. Treating influenza relies on drugs, such as Amantadine, that are becoming less effective due to viral evolution. But University of Chicago scientists have published computational results that may give drug designers the insight they need to develop the next generation of effective influenza treatment.
Everyone loves a grand slam: the crack of the bat, the arc of the ball as it sails over the fence, a tip of the batter’s cap, a triumphal trot around as the bases empty out, but really, it’s the lesser efforts that made it all possible—a double, a single, a walk—it’s the incremental gains that win the game. It’s called Small Ball. This year’s ASCO, absent the heavy hitters, was all about the small ball.
A new drug target to fight Alzheimer's disease has been discovered by a research team led by Gong Chen, a professor of biology and the Verne M. Willaman Chair in Life Sciences at Penn State. The discovery also has potential for development as a novel diagnostic tool for Alzheimer's disease.
Researchers are reporting promising treatment milestones for patients with deadly skin and lung cancers who are being treated with an experimental drug called MK-3475.
New research suggests that critically ill patients receiving steroids in a hospital’s intensive care unit (ICU) are significantly more likely to develop delirium. Results of the study suggest minimizing the use of steroids could reduce delirium in the ICU.
Technology currently used to disinfect food may help solve one of the most challenging problems in medicine today: the proliferation of bacteria resistant to antibiotics and other antimicrobial drugs.
Researchers have found a new target for treating chronic pain: an enzyme called PIP5K1C. The research shows that PIP5K1C controls the activity of cellular receptors that signal pain.
3-D printing promises to revolutionize engineering, and many speculate that it could have a huge impact on medicine, too. Many speculate that useful organs grown in the lab three-dimensionally on scaffolds is now closer to fact than fiction.
Results from neutron spin-echo analysis are an important advance towards enabling subcutaneous injections of concentrated biopharmaceuticals used to treat cancer and autoimmune disorders (e.g. arthritis, multiple sclerosis). The insights obtained could help drug companies reduce the viscosity and mitigate phase separation in injectable biopharmaceuticals.
In a proof-of-principle clinical trial, researchers have demonstrated that virotherapy— destroying cancer with a virus that infects and kills cancer cells but spares normal tissues— can be effective against the deadly cancer multiple myeloma.
A common antidepressant can dramatically halt growth of Alzheimer’s plaque. A team from Missouri and Pennsylvania report today in Science Translational Medicine this reduction occurs in both humans and mice. It gives the drug, the selective serotonin reuptake inhibitor (SSRI) citalopram, a possible future role as a prophylactic—the first in Alzheimer’s Disease (AD), if bigger studies are supportive.
Researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with Duchenne muscular dystrophy, a genetic muscle-wasting disease.
A team of researchers is creating molecules designed to shut down the Middle East respiratory syndrome coronavirus, or MERS-CoV, that recently arrived in the United States.
Scientists studying cancerous tumor tissues in a laboratory believe they have identified a potential new strategy to treat ovarian cancer by targeting ovarian tumor growth through the inhibition of the development of new tumor blood vessels.
The humble aspirin may have just added another beneficial effect beyond its ability to ameliorate headaches and reduce the risk of heart attacks: lowering colon cancer risk among people with high levels of a specific type of gene.
A team of researchers has developed a test that can rapidly assess several DNA repair systems, which could help determine individuals’ risk of developing cancer and help doctors predict how a given patient will respond to chemotherapy drugs.
The most effective way to tackle debilitating diseases is to punch them at the start and keep them from growing. Research shows that a small “molecular tweezer” keeps proteins from clumping, the first step of disorders such as Parkinson’s disease, Alzheimer’s disease and Huntington’s disease.
If you follow cancer biology, then you’ve probably heard of ubiquitin before. In a recent paper researchers provided a structural rationale for how ubiquitin helps RIG-I do its job— and how that might help keep the immune system from getting out of hand.
A team of scientists published details of how a class of drugs called “HDACis” drive muscle-cell regeneration in the early stages of dystrophic muscles, but fail to work in late stages. The findings are key to furthering clinical development of HDACis for Duchenne muscular dystrophy (DMD), an incurable muscle-wasting disease.